Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ: ANIP) and its peers.
The generic pharmaceutical industry operates on a volume-driven, low-cost business model, producing bioequivalent versions of branded drugs once their patents expire. These companies benefit from consistent demand for affordable medications, as they are critical to reducing healthcare costs. Generics typically face lower R&D expenses and shorter regulatory approval timelines compared to branded drug makers, enabling cost efficiencies. However, the industry is highly competitive, with intense pricing pressures, thin margins, and frequent legal challenges from branded pharmaceutical companies over patent disputes. Looking ahead, the industry is supported by tailwinds such as the role of AI in streamlining drug development (reverse engineering complex formulations) and manufacturing efficiency (optimize processes and remove inefficiencies). Governments and insurers' focus on reducing drug costs can also boost generics' adoption. However, headwinds include escalating pricing pressure from large buyers like pharmacy chains and healthcare distributors as well as evolving regulatory hurdles.
The 4 generic pharmaceuticals stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 1%.
Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 14.2% since the latest earnings results.
Best Q3: ANI Pharmaceuticals (NASDAQ: ANIP)
Founded in 2001, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic pharmaceutical products, with a focus on complex formulations and niche markets.
ANI Pharmaceuticals reported revenues of $148.3 million, up 12.5% year on year. This print exceeded analysts’ expectations by 1.5%. Overall, it was a very strong quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates and a solid beat of analysts’ EPS estimates.
“I am very pleased to report our third quarter results as we continue to execute against our purpose of ‘Serving Patients, Improving Lives,’” said Nikhil Lalwani, President & CEO of ANI.
ANI Pharmaceuticals achieved the highest full-year guidance raise of the whole group. The results were likely priced in, however, and the stock is flat since reporting. It currently trades at $58.22.
Is now the time to buy ANI Pharmaceuticals? Access our full analysis of the earnings results here, it’s free.
Amneal (NASDAQ: AMRX)
Founded in 2002, Amneal Pharmaceuticals (NASDAQ: AMRX) develops, manufactures, and distributes a diverse portfolio of pharmaceuticals.
Amneal reported revenues of $702.5 million, up 13.3% year on year, outperforming analysts’ expectations by 2.4%. The business had a satisfactory quarter with an impressive beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations.
Amneal achieved the biggest analyst estimates beat and fastest revenue growth among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 7.7% since reporting. It currently trades at $7.94.
Is now the time to buy Amneal? Access our full analysis of the earnings results here, it’s free.
Weakest Q3: Amphastar Pharmaceuticals (NASDAQ: AMPH)
Founded in 1996, Amphastar Pharmaceuticals (NASDAQ: AMPH) develops, manufactures, and markets injectable and inhalation products, focusing on critical care, emergency, and chronic conditions.
Amphastar Pharmaceuticals reported revenues of $191.2 million, up 5.9% year on year, falling short of analysts’ expectations by 1%. It was a softer quarter as it posted a miss of analysts’ EPS estimates.
Amphastar Pharmaceuticals delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 40.5% since the results and currently trades at $31.82.
Read our full analysis of Amphastar Pharmaceuticals’s results here.
Viatris (NASDAQ: VTRS)
Formed in 2020 through the merger of Mylan and Upjohn, Viatris (NASDAQ: VTRS) provides a portfolio of branded, generic, and over-the-counter medications as well as biosimilars aimed at addressing a wide range of therapeutic areas.
Viatris reported revenues of $3.75 billion, down 4.8% year on year. This number surpassed analysts’ expectations by 1%. Zooming out, it was a mixed quarter as it also logged a decent beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.
Viatris had the slowest revenue growth among its peers. The stock is down 8.8% since reporting and currently trades at $10.60.
Read our full, actionable report on Viatris here, it’s free.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
